文献速递肺栓塞与肺血管病

多族裔亚洲人群肺动脉高压14年随访:特征、生存与死亡预测因素

Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study.
PubMed 文献 · Respirology · 2018-09-04

该研究连续纳入2003至2016年转诊至肺高压专科中心的148例肺动脉高压患者,分析基线特征与生存情况,并采用多水平结构方程模型筛选死亡预测因素。结果显示最常见病因为先天性心脏病相关PAH(35.8%),REVEAL评分是死亡的最佳预测因素,评分>6为切点。

要点

  • 东南亚多族裔PAH队列最常见病因为先天性心脏病相关PAH(35.8%)。
  • 生存率1年85.8%、3年70.9%、5年66.9%、7年61.5%、10年55.4%。
  • REVEAL评分是死亡最佳预测因素,评分>6为切点。

核心结论

  • 该东南亚人群PAH注册研究的生存率与其他国家注册研究相当。
  • REVEAL评分在该人群中验证为良好的死亡预测因素。

研究设计与样本

  • 分析基线特征与生存,并基于前向预测变量选择程序应用多水平结构方程模型识别死亡相关预测因素。

主要发现

  • 148例患者中77%为女性,平均年龄50.8±15.9岁。
  • 最常见病因为先天性心脏病相关PAH(35.8%),其次为特发性PAH(29.7%)和结缔组织病相关PAH(24.3%)。
  • WHO功能分级以II级(48.6%)最常见,其次为III级(28.8%)。
  • 54.1%患者接受PDE5抑制剂单药治疗。
  • 生存率:1年85.8%、3年70.9%、5年66.9%、7年61.5%、10年55.4%。

关键数值与推荐

  • REVEAL评分为死亡最佳预测因素,评分>6为切点。
  • 其他死亡预测因素包括平均右心房压力、心率、病因、年龄和NT-proBNP。

临床怎么用

  • 在东南亚多族裔PAH人群中可采用REVEAL评分(>6为切点)辅助死亡风险评估。
  • 评估时应结合平均右心房压力、心率、病因、年龄和NT-proBNP等预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pulmonary arterial hypertension (PAH) is a rare and fatal disease. Data from Asia are lacking compared with the West. We aim to describe disease characteristics in an ethnically diverse South-East Asian population and assess predictors for survival. METHODS: We consecutively enrolled patients with PAH referred to our pulmonary hypertension specialty centre from January 2003 to December 2016. Baseline characteristics and survival were analysed. Based on a forward predictor selection procedure, a multi-level structural equation model was applied to identify predictors associated with mortality. RESULTS: Out of 148 patients enrolled, 77% were females and mean age was 50.8 ± 15.9 years. Racial distribution was consistent with our population census. The most common aetiologies were congenital heart disease-associated PAH (35.8%), idiopathic PAH (29.7%) and then connective tissue disease-associated PAH (24.3%). Most patients presented in World Health Organization (WHO) Functional Class (FC) II (48.6%), followed by FC III (28.8%). Majority of patients (54.1%) were on phosphodiesterase type 5 (PDE5) inhibitor monotherapy. Survival rates were 85.8% at the end of the first year, 70.9% at 3 years, 66.9% at 5 years, 61.5% at 7 years and 55.4% at 10 years. The Registry to Evaluate Early And Long-term PAH Disease Management (REVEAL) score (RS) was found to be the best predictor of mortality. A score > 6 was identified as a cut-off. Other predictors include mean right atrial pressure, heart rate, aetiology, age and N-terminal pro-brain natriuretic peptide. CONCLUSION: In this first registry study from a South-East Asian population, our survival rates are comparable with other national registries. The RS is validated in our population to be a good predictor of mortality.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Lim Y, Low TT, Chan SP, et al. Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study. Respirology. 2018. PMID: 30180305. doi:10.1111/resp.13392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。